Cigna said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

The FDA has approved medications like Zepbound and Wegovy for weight loss, which use the same active ingredient as the ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.